Klein G, Collinsworth W, Courbe A, Diez O, Domke I, Hänseler E, Haux P, Kattermann R, Knoke A, Lehmann P
Boehringer Mannheim GmbH, Federal Republic of Germany.
Wien Klin Wochenschr Suppl. 1992;191:43-7.
The CEDIA Phenobarbital assay has been evaluated in twelve clinical laboratories in Europe and U.S.A. on Boehringer Mannheim/Hitachi analysis systems. The evaluation focused on the analysis of imprecision and accuracy. Within-run and between-day coefficients of variations of the new assay were comparable to those of established routine methods. As demonstrated in an interlaboratory survey study with controls and human sera, results obtained in different laboratories showed a good agreement. The CEDIA Phenobarbital assay measured very accurately, as particularly confirmed by comparison with HPLC. It can be recommended as a reliable and practicable test for monitoring of phenobarbital on Boehringer Mannheim/Hitachi analyzers used in routine clinical chemistry.
CEDIA苯巴比妥检测法已在欧洲和美国的12家临床实验室中,在勃林格曼海姆/日立分析系统上进行了评估。评估重点在于不精密度和准确性分析。新检测法的批内和批间变异系数与既定常规方法的相当。正如在一项针对对照品和人血清的实验室间调查研究中所表明的,不同实验室获得的结果显示出良好的一致性。与高效液相色谱法比较尤其证实,CEDIA苯巴比妥检测法测量非常准确。对于在常规临床化学中使用的勃林格曼海姆/日立分析仪上监测苯巴比妥而言,它可作为一种可靠且实用的检测方法予以推荐。